Abstract: Provided are non-typeable Haemophilus influenzae vaccines useful for the treatment of chronic obstructive pulmonary disease and asthma in a patient. In certain aspects, the vaccine is a monobacterial vaccine. Bacterial strains for use in the vaccines of the present application are also provided.
Type:
Grant
Filed:
September 17, 2009
Date of Patent:
April 17, 2018
Assignee:
HUNTER IMMUNOLOGY LIMITED
Inventors:
Margaret Lorraine Dunkley, Robert Llewellyn Clancy
Abstract: There is provided a method for prophylaxis or treatment of asthma in an individual. The method comprises administering to the individual an effective amount of a Non-typable Haemophilus influenzae (NTHi) vaccine. The vaccine is typically an oral whole killed NTHi vaccine.
Type:
Grant
Filed:
March 14, 2008
Date of Patent:
November 22, 2016
Assignee:
HUNTER IMMUNOLOGY LIMITED
Inventors:
Margaret Dunkley, Robert Clancy, Allan William Cripps, Diana Christine Otczyk
Abstract: The present invention is concerned with novel compositions and vaccines useful for prophylactic an/or therapeutic treatment of mucosal infections, and in particular it is concerned with oral vaccines and with methods of enhancing mucosal resistance to infection or for treating established infections, of the respiratory tract.
Type:
Grant
Filed:
May 21, 2001
Date of Patent:
January 28, 2014
Assignee:
Hunter Immunology Limited
Inventors:
Robert Llewellyn Clancy, Gerald Pang, Margaret Lorraine Dunkley
Abstract: Provided are non-typeable Haemophilus influenzae vaccines useful for the treatment of chronic obstructive pulmonary disease and asthma in a patient. In certain aspects, the vaccine is a monobacterial vaccine. Bacterial strains for use in the vaccines of the present application are also provided.
Type:
Application
Filed:
September 17, 2009
Publication date:
August 25, 2011
Applicant:
Hunter Immunology Limited
Inventors:
Margaret Lorraine Dunkley, Robert Llewellyn Clancy
Abstract: There is provided a method for prophylaxis or treatment of asthma in an individual. The method comprises administering to the individual an effective amount of a Non-typable Haemophilus influenzae (NTHi) vaccine. The vaccine is typically an oral whole killed NTHi vaccine.
Type:
Application
Filed:
March 14, 2008
Publication date:
June 17, 2010
Applicant:
Hunter Immunology Limited
Inventors:
Margaret Dunkley, Robert Clancy, Allan William Cripps, Diana Christine Otczyk
Abstract: The present invention relates to novel oral compositions and vaccines, and in particular to oral vaccines for the prevention or therapy of candidiasis.
Type:
Grant
Filed:
June 19, 2001
Date of Patent:
February 2, 2010
Assignee:
Hunter Immunology Limited
Inventors:
Robert Clancy, Gerald Pang, Elahi Shokrollah
Abstract: There is described a method for selecting microbial isolates for use in oral killed vaccines against abnormal microbial colonisation of mucosal surfaces by the microbes. The method comprises evaluating capacity of a plurality of different isolates of a microbe to activate antigen responsive cells to provide activation data for each microbial isolate, and the effectiveness of the isolates in reducing infection of a mucosal surface by the microbe to provide clearance data for each microbial isolate. An isolate, the activation data and clearance data for which correlate and is optimal for generating mucosal immunity against the microbe compared to the, or each, other of the isolates, or an isolate the activation data for which is optimal and a further isolate the clearance data for which is optimal, compared to the, or each, other of the isolates, respectively, is then selected for use in the vaccine.
Type:
Application
Filed:
August 17, 2005
Publication date:
May 15, 2008
Applicant:
Hunter Immunology Limited
Inventors:
Robert Clancy, Phillip Comans, Gerald Pang
Abstract: There is disclosed a method for determining an administration regimen for an oral killed vaccine for use in immunising individuals in a population against an infection or disease. The method comprise administering the oral killed vaccine to one or more individuals in a population and identifying an indicative dosaging level of the vaccine which induces a reduction in immune system responsiveness to the vaccine in the one or more individuals. A further dosaging level that elicits an immune response in one or more individuals of the population without inducing the reduction in immune system responsiveness to the vaccine is then determined.
Type:
Application
Filed:
August 17, 2005
Publication date:
November 22, 2007
Applicant:
Hunter Immunology Limited
Inventors:
Robert Clancy, Phillip Comans, Gerald Pang